DK1368028T3 - Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering - Google Patents

Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering

Info

Publication number
DK1368028T3
DK1368028T3 DK02715052T DK02715052T DK1368028T3 DK 1368028 T3 DK1368028 T3 DK 1368028T3 DK 02715052 T DK02715052 T DK 02715052T DK 02715052 T DK02715052 T DK 02715052T DK 1368028 T3 DK1368028 T3 DK 1368028T3
Authority
DK
Denmark
Prior art keywords
ige
inhibition
modulation
benzimidazole compounds
cellular profiling
Prior art date
Application number
DK02715052T
Other languages
Danish (da)
English (en)
Inventor
Jagadish C Sircar
Mark L Richards
Michael W Major
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/090,044 external-priority patent/US6759425B2/en
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Application granted granted Critical
Publication of DK1368028T3 publication Critical patent/DK1368028T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02715052T 2001-03-12 2002-02-28 Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering DK1368028T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27526001P 2001-03-12 2001-03-12
US10/090,044 US6759425B2 (en) 1999-10-21 2002-02-27 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
PCT/US2002/006801 WO2002072090A1 (en) 2001-03-12 2002-02-28 Benzimidazole compounds for modulating ige and inhibiting cellular proliferation

Publications (1)

Publication Number Publication Date
DK1368028T3 true DK1368028T3 (da) 2007-12-27

Family

ID=34115140

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02715052T DK1368028T3 (da) 2001-03-12 2002-02-28 Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering

Country Status (20)

Country Link
US (2) US7282518B2 (xx)
EP (1) EP1368028B1 (xx)
JP (1) JP2004528304A (xx)
CN (1) CN1496257A (xx)
AR (1) AR034023A1 (xx)
AT (1) ATE369853T1 (xx)
BR (1) BR0208010A (xx)
CA (1) CA2441177A1 (xx)
CZ (1) CZ20032691A3 (xx)
DE (1) DE60221804T2 (xx)
DK (1) DK1368028T3 (xx)
ES (1) ES2291455T3 (xx)
HU (1) HUP0303460A3 (xx)
MX (1) MXJL03000027A (xx)
NZ (1) NZ528835A (xx)
PL (1) PL364230A1 (xx)
PT (1) PT1368028E (xx)
RU (1) RU2003127367A (xx)
WO (1) WO2002072090A1 (xx)
ZA (1) ZA200307916B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
WO2004041280A1 (en) * 2002-11-02 2004-05-21 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
ATE363905T1 (de) * 2003-04-17 2007-06-15 Janssen Pharmaceutica Nv 2-phenyl-benzimidazol und 2-phenyl-imidazo-4,5)- pyridin-derivate als checkpoint-kinase-cds1 (chk2)-hemmer zur behandlung von krebs
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法
US7485658B2 (en) * 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
KR20060115346A (ko) 2003-08-21 2006-11-08 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ―치환된 피라졸릴-아미딜-벤즈이미다졸릴 ｃ―ｋｉｔ억제제
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
EP1954287B2 (en) * 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP2298770A1 (en) * 2005-11-03 2011-03-23 ChemBridge Corporation Heterocyclic compounds as TrkA modulators
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
JP2010524892A (ja) * 2007-04-19 2010-07-22 ノバルティス アーゲー 代謝型グルタミン酸受容体−５の修飾因子としてのニコチン酸誘導体
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
CN103288803B (zh) * 2013-05-17 2017-10-31 郎恒元 苯并咪唑酰胺类化合物及其制备方法和应用
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
ES2973850T3 (es) * 2016-09-20 2024-06-24 Centre Leon Berard Derivados del benzoimidazol como agentes anticancerígenos
US11267786B2 (en) * 2018-06-01 2022-03-08 Merck Sharp & Dohme Corp. [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224512A1 (de) 1982-07-01 1984-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4510158A (en) * 1984-03-05 1985-04-09 Sterling Drug Inc. 2-Phenylindole derivatives, their use as complement inhibitors
DE3680636D1 (de) 1985-05-03 1991-09-05 Foxboro Co Regelung des trennungspunktes bei der destillation.
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US5206257A (en) * 1987-03-05 1993-04-27 May & Baker Limited Pesticidal method using 2-phenylimidazole derivatives
JP2630432B2 (ja) * 1987-08-24 1997-07-16 コニカ株式会社 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料
EP0397764A1 (en) 1988-02-02 1990-11-22 Schering Biotech Corporation Method of reducing immunoglobulin e responses
JP2700475B2 (ja) 1988-07-30 1998-01-21 コニカ株式会社 非線形光学材料および非線形光学素子
IT1232252B (it) 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
EP0415886A3 (en) 1989-08-30 1991-10-23 Ciba-Geigy Ag Aza compounds
FR2658511B1 (fr) * 1990-02-16 1992-06-19 Union Pharma Scient Appl Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant.
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
EP0469477B1 (en) 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5646281A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
JPH06263993A (ja) 1991-01-21 1994-09-20 Konica Corp アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
ATE150447T1 (de) 1992-06-15 1997-04-15 Celltech Therapeutics Ltd Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren
US5322847A (en) * 1992-11-05 1994-06-21 Pfizer Inc. Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4426625A1 (de) * 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) * 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
CZ30398A3 (cs) * 1995-08-02 1998-06-17 Newcastle University Ventures Limited Benzimidazolové sloučeniny, farmaceutický prostředek obsahující tyto sloučeniny a použití těchto sloučenin jako chemoterapeutických činidel
US6387938B1 (en) * 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
CA2232467A1 (en) * 1997-03-20 1998-09-20 Richard A. Glennon Imidazoles with serotonin receptor binding activity
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
DK0994890T3 (da) 1997-06-10 2003-12-01 Univ Michigan Benzimidazolderivater
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
CA2305370C (en) * 1997-09-26 2006-11-28 Gerald Mcmahon Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6303645B1 (en) * 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CA2332989A1 (en) 1998-05-22 1999-12-02 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of ige
US6369091B1 (en) * 1998-05-22 2002-04-09 Avanir Pharmaceuticals Benzimidazole analogs as down-regulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
ID28276A (id) 1998-10-23 2001-05-10 Hoffmann La Roche Heterolingkar nitrogen bisiklik
CA2349227C (en) * 1998-11-03 2008-02-05 Basf Aktiengesellschaft Substituted 2-phenylbenzimidazoles, the production thereof and their use
SI1131301T1 (sl) * 1998-11-17 2006-02-28 Abbott Gmbh & Co Kg 2-fenilbenzimidazoli in 2-fenilindoli, njihova priprava in uporaba
RU2001117757A (ru) 1998-11-27 2004-02-27 БАСФ Акциенгезельшафт (DE) Замещенные бензимидазолы и их применение в качестве ингибиторов поли(аденозиндифосфатрибоза)полимеразы
DE19918211A1 (de) 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6759425B2 (en) * 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6537994B2 (en) * 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
PL208238B1 (pl) 2001-03-12 2011-04-29 Janssen Pharmaceutica Nv Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP1613310A1 (en) * 2003-04-10 2006-01-11 Avanir Pharmaceuticals Imidazole derivatives for treatment of allergic and hyperproliferative disorders
JP2007501618A (ja) * 2003-08-08 2007-02-01 アバニール・ファーマシューティカルズ タンパク質輸送の選択的薬理学的阻害、および関連した、ヒト疾患を治療する方法

Also Published As

Publication number Publication date
BR0208010A (pt) 2004-12-21
DE60221804D1 (de) 2007-09-27
HUP0303460A2 (hu) 2004-03-01
ZA200307916B (en) 2004-09-03
US20040214821A1 (en) 2004-10-28
JP2004528304A (ja) 2004-09-16
NZ528835A (en) 2005-05-27
ATE369853T1 (de) 2007-09-15
US7282518B2 (en) 2007-10-16
US20070202133A1 (en) 2007-08-30
AR034023A1 (es) 2004-01-21
CA2441177A1 (en) 2002-09-19
HUP0303460A3 (en) 2004-07-28
ES2291455T3 (es) 2008-03-01
MXJL03000027A (es) 2004-04-30
EP1368028B1 (en) 2007-08-15
EP1368028A1 (en) 2003-12-10
PL364230A1 (en) 2004-12-13
DE60221804T2 (de) 2008-05-15
WO2002072090A1 (en) 2002-09-19
CN1496257A (zh) 2004-05-12
RU2003127367A (ru) 2005-03-20
CZ20032691A3 (en) 2004-04-14
PT1368028E (pt) 2007-11-26

Similar Documents

Publication Publication Date Title
DK1368028T3 (da) Benzimidazolforbindelser til IgE-modulering og inhibering af cellulær profi-ferering
ATE484496T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
DE60221977D1 (de) Pro-pharmakon von cox-2-inhibitoren
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
NO20035604D0 (no) Skiferhydreringsinhiberingsmiddel og fremgangsmåte for anvendelse derav
DE60234125D1 (de) E inhibitoren
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
ATE333463T1 (de) Selektive dipeptidische inhibitoren von kallikrein
DK1501508T3 (da) Inhibitorer af histondeatylase
DK1656370T3 (da) Heterocykliske biarylforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DE60103935D1 (de) Imidazol-5-yl-2-anilino-pyrimidine als inhibitoren der zellproliferation
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
EE200300450A (et) Metalloproteinaasi inhibiitorid
DK1458447T3 (da) Kombination af cytokrom-p450-beroende proteasinhibitorer
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1400522T3 (da) Forbindelser til behandling af impotens
DE60229669D1 (de) X-2 inhibitoren
DK1392822T3 (da) Dobbelttransficeret cellelinie anvendelig til identifikation af transporthæmmere
DE60235470D1 (de) N-heterocyclische inhibitoren der expression von tnf-alpha
DE60124397D1 (de) Inhibitoren von serinproteasen
DK1360282T3 (da) Fremgangsmåde til inaktivering af TSE
SE0100694D0 (sv) DHFR inhibitors